# NCT03089203 (NCT03089203)

> CART-PSMA-TGFβRDN Cells for Castrate-Resistant Prostate Cancer

No report yet. It can be ordered.

- Indication: metastatic castration-resistant prostate cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03089203
- Phase: PHASE1
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: University of Pennsylvania
- Conditions: Prostate Cancer
- Interventions: CART-PSMA-TGFβRDN cells; Cyclophosphamide; Fludarabine
- Enrollment: 23
- Primary outcome: Occurrence of study related adverse events, laboratory toxicities and clinical events that are possibly, likely, or definitely related to study participation.
- Primary outcome: Clinical feasibility is defined as the frequency of subjects enrolled on this protocol who do not receive CART-PSMA-TGFβRDN cells.
- Primary outcome: Manufacturing feasibility is determined by the frequency of product release failures and the occurrence of dose failures (inability to meet target dose).

## Indexed commentary on NCT03089203 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=nct03089203